Study Finds Crizotinib Does Not Extend Disease-Free Survival in Early-Stage ALK+ Lung Cancer
A recent study shows that crizotinib does not improve disease-free survival in patients with resected early-stage ALK-positive non-small cell lung cancer, guiding future treatment strategies.
Recent clinical trial results presented at the 2025 World Conference on Lung Cancer reveal that crizotinib, a targeted therapy approved for advanced ALK-positive non-small cell lung cancer (NSCLC), does not provide a benefit in preventing disease recurrence when used as an adjuvant treatment in patients with early-stage, resected ALK+ NSCLC. The Phase II E4512 trial studied patients with stage IIA–IIIB disease, confirmed by FISH, IHC, or NGS, who underwent surgery with clean margins and received no prior ALK inhibitor therapy.
Participants were randomized to either observation or receive crizotinib at 250 mg twice daily for up to two years, with the primary goal of assessing disease-free survival (DFS). The trial enrolled 166 patients between 2014 and 2024, with most remaining confirmed ALK+ upon central testing. Results showed no significant difference in DFS: median DFS was approximately 73 months for the crizotinib group versus 75 months for observation, indicating no meaningful clinical benefit. Overall survival data were immature, with medianOS not reached in either group.
Safety data indicated that about one-third of patients experienced grade 3 adverse events, commonly diarrhea and edema, with some requiring dose reductions or treatment discontinuation. Notably, 4% of patients experienced grade 4 events such as stroke.
The trial was subsequently halted after the FDA approved adjuvant alectinib for this patient population. Dr. David Gerber and colleagues concluded that adjuvant crizotinib does not improve disease-free survival in resected early-stage ALK+ NSCLC, emphasizing the need for alternative strategies in this setting.
This landmark study highlights the importance of evidence-based approaches in the management of early-stage lung cancer and guides future research efforts.
(Source: https://medicalxpress.com/news/2025-09-crizotinib-disease-free-survival-resected.html)
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Repositioning Rheumatoid Arthritis Medication to Combat COVID-19-Induced Inflammation
A promising study reveals that iguratimod, a drug used for rheumatoid arthritis, may help reduce excessive inflammation in COVID-19 patients without compromising immune response. This could lead to safer therapies for managing severe COVID-19 complications.
WHO Supports Access to Affordable Weight-Loss Medications and Promotes Generic Alternatives
WHO recommends key weight-loss medications for global use and urges the production of affordable generic versions to improve access in developing countries, aiming to combat obesity and related health issues worldwide.
Wildfire Smoke Exposure Elevates Risks of Dementia, Asthma, and Other Health Conditions
New studies reveal that wildfire smoke significantly increases the risk of dementia, asthma, and other health issues, emphasizing the importance of air quality management and climate action.
Researchers Develop Targeted Approach to Separate Pain Relief from Inflammation in NSAIDs
New research from NYU reveals that targeting a specific prostaglandin receptor can alleviate pain without suppressing essential inflammation, paving the way for safer pain therapies.